ArticleJournal of thoracic disease2018
Evaluation of the performance of serum miRNAs as normalizers in microRNA studies focused on cardiovascular disease.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study.Nutrients · 2022Trial
- Comprehensive evaluation of reference miRNA for extracellular miRNA quantification in CKD.Methods (San Diego, Calif.) · 2026Article
- Identification of Stable Housekeeping Genes for miRNA Expression Studies in a Mouse Unilateral Ureteral Obstruction Model.Biochemical genetics · 2026Article
- Serial measurement of circulating cardiovascular-enriched microRNAs in patients with ischaemic heart disease - a five-year longitudinal study.Bioscience reports · 2025Article
- Differential expression of miR-23a-3p/-210-3p and /-18b-5p in sudden sensorineural hearing loss patients: A North American cohort study.Scientific reports · 2025Article
- Potential diagnostic value of circulating miRNAs in HFrEF and bioinformatics analysis.Heliyon · 2024Article
- Multicenter, prospective, observational study for urinary exosomal biomarkers of kidney allograft fibrosis.Scientific reports · 2024Observational
- Differential Effect of Extracellular Vesicles Derived fromInternational journal of molecular sciences · 2023Article
- Identification of RNU44 as an Endogenous Reference Gene for Normalizing Cell-Free RNA in Tuberculosis.Open forum infectious diseases · 2022Article
- microRNAs in newborns with low birth weight: relation to birth size and body composition.Pediatric research · 2022Article
- Characterization of Adrenal miRNA-Based Dysregulations in Cushing's Syndrome.International journal of molecular sciences · 2022Article
- Factors influencing circulating microRNAs as biomarkers for liver diseases.Molecular biology reports · 2022Review
- miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis.International journal of molecular sciences · 2022Article
- Considerations and Suggestions for the Reliable Analysis of miRNA in Plasma Using qRT-PCR.Genes · 2022Review
- miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1.Molecular therapy. Methods & clinical development · 2021Article
- Long non-coding RNAs in oncourology.Non-coding RNA research · 2021Review
- Circulating microRNA Expression in Cushing's Syndrome.Frontiers in endocrinology · 2021Article
- Differential Expression of Circulating Plasma miRNA-370 and miRNA-10a from Patients with Hereditary Hemorrhagic Telangiectasia.Journal of clinical medicine · 2020Article
- The current state of MiRNAs as biomarkers and therapeutic tools.Clinical and experimental medicine · 2020Review
- A systemic approach to screening high-throughput RT-qPCR data for a suitable set of reference circulating miRNAs.BMC genomics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew study has been done to evaluate the stability and superiority of normalizers for serum microRNA (miRNA) study in cardiovascular disease. Therefore, the aim of this study is to assess the suitability of several common normalizers (miR-16, SNOU6, 5S, miR-19b, miR-24, miR-15b, let 7i) in cardiovascular disease.
methodsWe evaluated the stability of the seven circulating miRNAs as reference genes in the blood samples from patients with cardiovascular disease [heart failure (HF) and hypertension] and healthy people. Stability was quantified by combining BestKeeper, NormFinder and comparative delta Cq analysis.
resultsA total of 62 subjects were included in this study, of which 25 patients were with HF, 10 patients were with hypertension, and 27 were healthy people. The analysis from both BestKeeper and comparative delta ct analysis demonstrated that let-7i and miR-16 showed the best performance [the standard deviations (SD) in BestKeeper for let-7i and miR-16 were 0.60 and 0.72, and the mean SD in comparative delta ct analysis for let-7i and miR-16 were 1.79 and 1.82, respectively], while SNOU6 and 5S had the highest variability. In NormFinder analysis, miR-15 show best stability (ρ=0.029), followed by miR-19b (ρ=0.037), let-7i (ρ=0.064), SNOU6 (ρ=0.064), 5S (ρ=0.064), miR-16 (ρ=0.064), while miR-24 (ρ=0.075) showed worst stability.
conclusionsThis study pointed out that in the serum studies focused on cardiovascular disease, let-7i and miR-16 had the best performance, while SNOU6 and 5S were not suitable as reference gene. This study indicate that the selection of an optimal reference genes is important to get an accurate result in serum miRNA studies, the findings are of clinical significance to guide the further miRNA studies or tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.